01 January 2005
Infliximab and surgical therapy in a patient with severe crohn’s disease: a case report
Zsolt Barta, Zsuzsa Ress, Zoltán Csiki, Katalin Dévényi, László Buris, László Tóth, Margit ZeherCase Rep Clin Pract Rev 2005; 6:281-284 :: ID: 438975
Abstract
Background: The treatment with infliximab is highly effective in refractory and fistulising Crohn’s disease. As Crohn’s disease represents a major challenge for surgery and since the conservative therapeutical approach with anti-TNF antibodies always requires consideration of potential benefits and risks for the patient as well, the optimal treatment requires a close interdisciplinary approach.
Case Report: Here we describe the case of a young male with a history of rapidly manifesting Crohn’s disease(and unrecognized celiac disease) whose conflicting findings presented dilemma to use infliximab in consideration of its contraindications. After multilateral discussions with specialists and judicious revision of his results, the patient was treated successfully and minimal surgical intervention was needed instead of heroic surgery. A minority of patients with celiac disease who fail to respond to a gluten-free diet may require therapy with immunomodulating drugs. Our patient’s remission
was not induced by infliximab but with gluten-free diet.
Conclusions: A 2-year follow-up demonstrated distinct improvement. Celiac disease poses a therapeutic challenge to clinicians and carefully selected patients may benefit from anti-TNF therapy although our experience does not strengthen this concept.
Keywords: Crohn’s disease, celiac disease, Surgery, infliximab
SARS-CoV-2/COVID-19
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936574
In Press
20 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936252
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936318
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936377
Most Viewed Current Articles
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935355
Am J Case Rep 2022; 23:e935355